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Abstract
Background Given the fact that prostate cancer incidence
will increase in the coming years, new prognostic biomark-
ers are needed with regard to the biological aggressiveness
of the prostate cancer diagnosed. Since cytokines have been
associated with the biology of cancer and its prognosis, we
determined whether transforming growth factor beta 1
(TGF1), interleukin-7 (IL-7) receptor and IL-7 levels add
additional prognostic information with regard to prostate
cancer-speciWc survival.
Materials and methods Retrospective survival analysis of
forty-four prostate cancer patients, that underwent radical
prostatectomy, was performed (1989–2001). Age, Gleason
score and pre-treatment PSA levels were collected. IL-7,
IL-7 receptor and TGF1 levels in prostate cancer tissue
were determined by quantitative real-time RT-PCR and
their additional prognostic value analyzed with regard to
prostate cancer survival. Hazard ratios and their conWdence
intervals were estimated, and Akaike’s information crite-
rion was calculated for model comparison.
Results The predictive ability of a model for prostate can-
cer survival more than doubled when TGF1 and IL-7 were
added to a model containing only the Gleason score and
pre-treatment PSA (AIC: 18.1 and AIC: 6.5, respectively).
Conclusion IL-7 and TGF1 are promising markers to
indicate those at risk for poor prostate cancer survival. This
additional information may be of interest with regard to the
biological aggressiveness of the diagnosed prostate cancer,
especially for those patients screened for prostate cancer
and their considered therapy.
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Introduction
According to UN Projections, the population aged 60 or
over increases from 475 million in 2009 to 1.6 billion in the
year 2050. Since prostate cancer is primarily a disease of
elderly males, one could expect an increase of prostate can-
cer incidence in the coming years. In addition, an extra
increase could be expected as a consequence of screening
for prostate cancer, for example, using prostate-speciWc
antigen (PSA) [1, 2].
Histologic tumor grading of prostate cancer is essential for
the assessment of prognosis. Prognosis refers to the expected
biologic potential of a patient’s prostate cancer to spread to
other organs, that is, to metastasize. Prognosis is, among oth-
ers, based upon PSA pre-treatment level and the Gleason
score. The Gleason grading system uses the histological pat-
tern of neoplastic cells in hematoxylin-eosin-stained sections
and is largely subjectively scored by the pathologist [3].
Gleason scores can be derived from both biopsy and rad-
ical prostatectomy samples. The biopsy-derived Gleason
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tumor because of sampling error [4–6]. Furthermore, a high
variability has been described in the way clinicians use
prostate needle biopsy-based pathology reports [7–9].
Despite the inter and intraobserver variabilities of Gleason
score determination, and discordance in the Gleason score
between biopsy and radical prostatectomy specimens, the
Gleason score remains the most important prognostic factor
for prostate cancer clinical outcome and therefore strongly
inXuences decisions regarding options for therapy [4–6, 10,
11]. The above limitations of the Gleason score indicate the
need for additional, and preferably objectively measured
information on the biological aggressiveness of the diag-
nosed prostate cancer, especially while screening for pros-
tate cancer.
Cytokines have been associated with the biology of
cancer and its prognosis. These low molecular weight
molecules have signiWcant roles, not only in immune/
inXammatory systems, but also in hematopoiesis, the acute
phase response, and multiple other functions. SpeciWc cyto-
kines have been found to be elevated in plasma of patients
with various malignancies including prostate cancer. For
example, earlier studies suggested a relation between
increased levels of interleukin-4 (IL-4), IL-6 and IL-10
with prostate malignancy [12, 13]. Other studies reported
patients with metastatic prostate cancer which were associ-
ated with increased transforming growth factor beta
(TGF) serum levels, and TGF1 accumulation in primary
and metastatic prostate cancer tissue samples [14–18]. Fur-
thermore, an antagonistic relationship has been suggested
for TGF and IL-7. TGF down regulates IL-7 secretion
[19], whereas IL-7 inhibits the production of TGF-beta1 by
tumor cells [20].
In non-cancer cells, TGF stops cell proliferation,
induces diVerentiation, or promotes apoptosis. In cancer
cells, mutations of the TGF pathway confer resistance to
growth inhibition by TGF, resulting in uncontrolled cell
proliferation. The increase of TGF production in cancer
cells also stimulates angiogenesis and suppresses the activi-
ties of inWltrating immune cells, thereby facilitating the
tumor to escape immunosurveillance [21]. On the other
hand, IL-7 promotes T cell cytolytic, innate responses, anti-
tumor reactivity in lung cancer, and prolonged survival in
mice after whole cell vaccination with cells that are able to
secrete mIL-7 [22–25]. Loss of epithelial IL-7 in prostate
cancer tissue is associated with a severe depletion of pros-
tate-associated lymphocytes [26].
Therefore, we hypothesize that TGF1, the IL-7 receptor
and IL-7 may add additional objective information to Glea-
son score and pre-treatment PSA level-based prognosis of
prostate cancer-speciWc survival. In this retrospective study
in forty-four patients with localized prostate cancer who
underwent radical prostatectomy, we tested this working
hypothesis. Prostate cancer-speciWc survival was examined
in relation to the Gleason score, pre-treatment PSA level,
age, and prostate tissue expression levels of IL-7, TGF1
and the IL-7 receptor.
Materials and methods
Patient samples
Clinical prostate cancer samples (1989–2001) were
obtained from the tissue bank of the Erasmus University
MC. Samples were snap frozen and stored in liquid nitro-
gen. All samples contained at least 70% tumor cells. Col-
lection of patient samples was performed according to
national legislation concerning ethical requirements. The
Erasmus MC Medical Ethics Committee, according to the
Medical Research Involving Human Subjects Act,
approved the use of these samples. Population characteris-
tics are shown in Table 1, follow-up was completed until
December 31, 2008.
RNA isolation and gene expression analysis
RNA from the prostate cancer samples was using RNABee
reagent as described by the manufacturer (Tel-test, Inc.,
Friendswood, TX, USA). The RT reaction was performed
with 1 g RNA from the samples with oligo-(dT)12–18
primer (Invitrogen) and pre-incubated for 10 min at 70°C.
Table 1 Characteristics of forty-four patients with localized prostate
cancer
Cytokine levels determined in prostate cancer tissues of the 44 prostate
cancer patients studied. IL-7 interleukin 7, IL-7r interleukin 7 receptor,
TGF1 tumor growth factor beta 1, PSA prostate-speciWc antigen, IQR
interquartile range
Continuous Log-transformed
Age at treatment, 
median (IQR)
61.0 (9.5)
PSA pre-treatment (ng/ml), 
median (IQR)
10.8 (13.8) 3.4 (1.6)







Cytokine tissue levels (expression/PBDG)
IL-7 6.0 (6.0) 2.6 (1.3)
IL-7r 3.4 £ 107 (7.2 £ 107) 25.0 (2.5)
TGF1 44.5 (48.5) 5.5 (1.4)123
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added and incubated for 2 min at 37°C. The RT reaction
was initiated by MMLV-RT and incubated for 1 h at 37°C.
After this, the reaction was maintained for 10 min at 90°C
and immediately thereafter frozen. Quantitative real-time
RT-PCR analysis was done with an ABI Prism 7700
Sequence Detection System (Applied Biosystems) using
AmpliTaq Gold according to the manufacturer’s speciWca-
tions (Applied Biosystems, Foster City, CA). The FAM-
labeled primers and probes for Taqman Gene Expression
Assays were obtained from Applied Biosystems (IL-7,
Hs00978525_m1; IL-7receptor, Hs00902334_m1; TGFbeta1,
Hs00998133_m1). The CT readings of target gene
expressed were normalized to an endogenous reference and
relative to a calibrator. The endogenous reference was Por-
phobilinogen deaminase (PBDG); a mixture of cDNAs of
prostate carcinoma xenografts was used as the calibrator
[27, 28].
Statistics
With death from prostate cancer as event, and death from
other causes considered as censored events, log-rank tests
and Cox regressions were performed using base 2 log-
transformed pre-treatment PSA levels, and base 2 log-trans-
formed IL-7, IL-7receptor and TGF1 relative expression
levels. Post-surgical information such as pTNM staging
was omitted in this study because of our interest in a possi-
ble stronger pre-surgical prognosis, at present mainly based
upon the pre-treatment PSA levels and the Gleason score.
The relation of the variables on prostate cancer survival
was determined, along with Akaike’s information criterion
(AICX2)  for the comparison of the models. The AICX2  mea-
sures the improvement in prognostic value of a model with
respect to a model with a sole constant as a predictor
(=null-model). Therefore, if two models are compared
(using the same underlying dataset), the model with the
highest AICX2  is to be preferred. Please note that AIC is
diVerent than the mentioned AICX2.  AIC is deWned as the
¡2log likelihood of the observed data at hand under the
assumed model, corrected for the number of degrees of
freedom. It refers to the quality of the Wt. A perfect Wt yields
a ¡2log likelihood of zero, a less than perfect Wt a value




Forty-four prostate cancer patients were studied, 7 patients
died of prostate cancer. All patients underwent radical pro-
statectomy and had clinical Wndings reviewed. Patient char-
acteristics and relative cytokine expression levels are
reported in Table 1. The median age at diagnosis was
61 years with an interquartile range (IQR) of 9.5 years. The
median PSA level pre-treatment was 10.8 ng/ml (IQR:
13.8 ng/ml), and the median Gleason score was 6. Median
cytokine levels in the examined prostate cancer tissue sam-
ples were 6.0 (IQR: 6.0), 3.4 £ 107 (IQR 7.2 £ 107) and
44.5 (IQR 48.5) for IL-7, IL-7receptor and TGF1, respec-
tively. The median follow-up time was 11.8 years (IQR
5.3 years) after radical prostatectomy.
Analysis of prostate cancer-speciWc survival
First a log-rank test was performed using the individual
variables in relation with prostate cancer-speciWc survival.
Both the Gleason score (P = 0.00) and pre-treatment PSA
levels (P = 0.00) did show a relation with prostrate cancer-
speciWc survival, as well as IL-7 receptor (P = 0.00), IL-7
(P = 0.04) and TGF1 (P = 0.00). Age at diagnosis
(P = 0.91) did not indicate to be related to prostate cancer
death. Contribution of separate variables to prostate cancer-
speciWc survival is summarized in Table 2.
Secondly, multivariate analysis with regard to prostate
cancer-speciWc survival was performed (Table 3). The
basic model included the Gleason score (hazard ratio (HR)
2.4, conWdence interval (CI) 1.0–6.1) and PSA levels pre-
treatment (HR 1.4 CI 0.8–2.2), since these two parameters
are, among others, used for decision-making on prostate
cancer treatment. This basic model was extended using the
other variables. Extending the basic model with basic
model with the variables IL-7receptor (HR 0.52 CI 0.22–
1.20) or age (HR 0.96 CI 0.85–1.09) did not improve the
prediction of disease speciWc survival. The best model for
prediction of disease-speciWc survival included the log-
transformed pre-treatment PSA levels (HR 1.6 CI 0.8–3.0),
log-transformed TGF1 expression (HR 10.4 CI 2.1–52.0),
log-transformed IL-7 expression (HR 0.1 CI 0.0–0.9) and
Table 2 Univariate analysis of individual variables with regard to
prostate cancer survival
The variables IL-7 expression, IL-7 receptor expression, TGF1
expression and pre-treatment PSA levels were base 2 log-transformed
before analysis. IL-7 interleukin 7, IL-7r = interleukin 7 receptor,
TGF1 tumor growth factor beta 1, PSA prostate-speciWc antigen
X2 P-value
Gleason score 47 0.00
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6.5 and 18.1 for the basic model and the Wnal model,
respectively.
Discussion
We analyzed the data of forty-four prostate cancer patients
for prostate cancer-speciWc survival in relation with the
Gleason score, PSA-level pre-treatment, age at diagnosis,
and the expression levels of IL-7, TGF1 and the IL-7
receptor within prostate cancer tissue samples.
Besides the Gleason scores and pre-treatment PSA lev-
els, also the IL-7 receptor, IL-7 and TGF1 were related to
prostate cancer-speciWc survival (log-rank test, Table 2).
The relation of the Gleason score and PSA levels with pros-
tate cancer prognosis has been reported since the 1960s
[3, 29]. Elevated levels of TGF1 are associated earlier to
be involved in the development of prostate cancer in animal
models and accumulation of TGF1 in primary and meta-
static prostate cancer tissue samples [15–18]. Pre-treatment
biomarker levels of for example vascular endothelial
growth factor, IL-6 but also TGF1 have been indicated to
improve the accuracy of post-prostatectomy for prediction
of biochemical recurrence, when incorporated into standard
predictive models. It was suggested that this incorporation
might allow more accurate identiWcation of patients who
are likely to fail RP thereby allowing more eYcient deliv-
ery of adjuvant therapy [30, 31]. It has however also been
reported that plasma TGF1 was not elevated in prostate
cancer patients compared to non-prostate cancer patients.
Plasma TGF1 levels did not correspond to Gleason score
or PSA levels in these patients; however, urinary TGF1
levels did [32]. On the other hand, one should take into
account that urinary markers might reXect a renal process
rather than a prostate cancer process, as well as the varia-
tion of serum markers due to underlying disease or age
[33–35]. Even though it is diYcult to compare these studies
because diVerent methods were used in collection and prep-
aration of patient samples, more objective TGF1 detection
in plasma or other cytokines related to prostate cancer
could ease in determination of the prostate cancer process
and treatment. Decreased IL-7receptor expression has not
been reported before in relation with prostate cancer tissue.
However, reduced numbers of IL-7 receptor expressing
immune cells and IL-7-signaling defects in peripheral
blood were observed in patients with breast cancer [36].
Epithelial IL-7 production was reported to support intra-
prostatic lymphocyte survival. Its loss in prostate cancer is
associated with a severe depletion of prostate-associated
lymphocytes and points to a tumor escape mechanism [26].
Functional cytokines are classiWed in pro-inXammatory
(Th1) and anti-inXammatory (Th2). It has been reported
that high levels of the anti-inXammatory cytokines IL-4 and
IL-10 are associated with elevated levels of PSA [13]. IL-6
is an interleukin that acts as both a pro-inXammatory and
anti-inXammatory cytokine. In relation to prostate cancer,
elevated levels of IL-6 have been associated with elevated
levels of PSA and disease activity [12, 13]. TGF1 also
belongs to the anti-inXammatory cytokines, and in relation
with prostate cancer, elevated levels of TGF1 were corre-
lated to disease progression [14–18], which is also observed
in our presented model. IL-7, on the other hand, is a pro-
inXammatory cytokine. In our model, low levels of IL-7 are
associated with poor prostate cancer survival, which reX-
ects the suggested antagonistic relationship between TGF
and IL-7 [19, 20]. The overall picture for prostate cancer
suggests that elevation of anti-inXammatory cytokines is
related to poor prostate cancer prognosis, while elevation of
pro-inXammatory cytokines reduces the risk [37, 38].
Multivariate models based on the Gleason score and pre-
treatment PSA levels extended with other variables have
been validated in this study. The Wnal model for prediction
of prostate cancer-speciWc survival included the Gleason
score, pre-treatment PSA levels, TGF1 expression and
IL-7 expression. When Cox regression was performed, haz-
ard ratios, together with their conWdence intervals, were
presented (P-values lower or equal to 0.05 were considered
statistically signiWcant), along with Akaike’s information
criterion (AICX2).  A model with base 2 log-transformed
Table 3 Multivariate analysis using Cox regression of the basic model, including pre-treatment PSA levels and Gleason score
This basic model was extended using the log-transformed IL-7 expression and TGF1 expression for the best prediction of disease speciWc sur-
vival. The AICX2  were 6.5 and 18.1 for the basic model and the Wnal model, respectively. IL-7 interleukin 7, TGF1 tumor growth factor beta 1,
PSA prostate-speciWc antigen, HR hazard ratio, CI conWdence interval
Multivariate basic model Multivariate Wnal model
HR CI P-value HR CI P-value
Gleason score 2.4 0.97–6.11 0.06 4.2 1.01–17.68 0.05
Pre-treatment PSA 1.4 0.85–2.22 0.20 1.6 0.80–3.04 0.19
TGF1 10.4 2.01–52.00 0.00
IL-7 0.1 0.02–0.86 0.03123
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pared to non-log-transformed variables (AICX2:  18.05 and
15.89, respectively).
The additional value of TGF1 and IL-7 with respect to
predicting the natural course of disease was evident, since
the prognostic value of the model was almost three times
higher than a model including only Gleason score and pre-
treatment PSA (AICX2  18.1 vs. AICX2  6.5, respectively).
This model also reXects the suggested antagonistic behav-
ior of TGF1 and IL-7. High levels of TGF1 corre-
sponded with a higher risk, and high IL-7 levels with
reduced risk of prostate cancer death. Given the limitations
of Gleason grading, the Wnal model was analyzed without
the Gleason score (data not shown). This model showed to
be less predictive for prostate cancer survival, and the
AICX2  was lower (AIC 13.5) compared to the Wnal model
including the Gleason score (AIC 18.1). Therefore, it was
concluded that the predictive value of Gleason score,
despite its limitations, could not be omitted in a predictive
model for prostate cancer survival.
Given the limited number of patients in this study, these
results need to be externally validated in studies with larger
prostate cancer patient populations [39]. Nevertheless, our
results indicate that IL-7 and TGF1 are promising markers
to indicate those patients at risk for poor survival. Objec-
tively measured TGF1 and IL-7 expression levels in pros-
tate cancer tissues can be of additional value with respect to
the biological aggressiveness of the diagnosed prostate can-
cer and the considered therapy, when incorporated into a
predication model containing the Gleason score and pre-
treatment PSA levels. If pre-surgical TGF1 and IL-7
expression levels could be measured in serum or urine [32],
with the same predictive properties as TGF1 and IL-7
derived from prostate cancer tissue, the application of the
former is likely to be preferred.
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